Adalimumab (ADA) is a human recombinant IgG1 monoclonal antibody that binds to soluble and membrane-bound TNFα and is utilized as therapy for RA treatment and other immune-mediated diseases (IMIDs) such as axial spondyloarthritis and inflammatory bowel disease (4). Here, ADA is linked to rheumatoid arthritis.